Investors - Press Releases
Infectious Disease Connectâ Announces Precision Dosing Powered by Tabula Rasa HealthCare's DoseMeRxä
The integration of DoseMeRx with ILÚM Insight will provide ID Connect customers with instant access to personalized dosing for vancomycin and other antimicrobials, optimizing pharmacy workflow and improving patient safety.
"Partnering with DoseMeRx, a leader in precision dosing, will bring this important capability to our customers in a seamless fashion, while further enhancing our already differentiated Antimicrobial Stewardship solution," said
ID Connect's ILÚM Insight platform provides physicians and pharmacists real-time antimicrobial usage and resistance data to help them select appropriate therapy, while managing costs, toxicity and the potential for further resistance and transmission of infection. Integrating DoseMeRx will enable ID Connect customers to easily individualize the dosing of antimicrobials including vancomycin – one of the most commonly used antibiotics in hospitals today.
"TRHC is dedicated to improving health through innovative technologies and service models, and ID Connect's mission is aligned with ours," said TRHC Chairman and CEO
According to TRHC Executive Vice President for DoseMeRx,
DoseMeRx is a TRHC solution. It is the first precision dosing software developed specifically for clinical practice. The DoseMeRx clinical decision support platform empowers healthcare providers to optimize dosing of high-risk parenteral medications to streamline operations, reduce adverse drugs events, decrease costs and improve patient outcomes. For more information on DoseMeRx, visit doseme-rx.com
About Infectious Disease Connect
Spun out of leading academic medical center
This press release includes forward-looking statements that we believe to be reasonable as of today's date, including statements regarding Medication Risk Mitigation technology. Such statements are identified by use of the words "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects," "should," and similar expressions. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC, including those factors discussed under the caption "Risk Factors" in our most recent annual report on Form 10-K, filed with the
TRHC Media Contact: Dianne Semingson, email@example.com, T: (215) 870-0829; TRHC Investors: Frank Sparacino, firstname.lastname@example.org, Office 866.648.2767; IDC Media Contact: Wendy Zellner, ZellnerWL@upmc.edu, Office: 412-586-9777, Mobile: 412-973-7266